Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cell therapies for the sports medicine and severe burn care markets in the United States. The company is headquartered in Cambridge, Massachusetts.
| Revenue (TTM) | $306.30M |
| Gross Profit (TTM) | $228.38M |
| EBITDA | $31.15M |
| Operating Margin | 0.56% |
| Return on Equity | 7.16% |
| Return on Assets | 2.43% |
| Revenue/Share (TTM) | $6.04 |
| Book Value | $7.01 |
| Price-to-Book | 7.17 |
| Price-to-Sales (TTM) | 8.66 |
| EV/Revenue | 8.43 |
| EV/EBITDA | 66.82 |
| Quarterly Earnings Growth (YoY) | 18.90% |
| Quarterly Revenue Growth (YoY) | 22.50% |
| Shares Outstanding | $51.21M |
| Float | $50.58M |
| % Insiders | 1.19% |
| % Institutions | 109.16% |
Volatility is currently expanding
Vericel NASDAQ: VCEL raised its full-year revenue and profitability outlook after third-quarter sales rose 26%, led by growth in its MACI cartilage repair product and a record quarter for its burn care business.
Vericel Corporation ( VCEL ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Eric Burns - Vice President of Finance & Investor Relations Dominick C. Colangelo - CEO, President & Director Joseph Mara - CFO & Treasurer Conference Call Participants Joshua Jennings - TD Cowen, Research Division Caitlin Roberts - Canaccord Genuity Corp., Research Division Richard Newitter - Truist Securities, Inc., Research Division Ryan Zimmerman - BTIG, LLC, Research Division Samuil-Hrabar Gatev - Leerink Partners LLC, Research Division Mason Carrico - Stephens Inc., Research Division Presentation Operator Good day, and welcome to the Vericel Corporation Third Quarter 2026 Earnings Call.
Vericel Corporation (VCEL) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.1 per share a year ago.
Total Revenue Growth of 26% to $85.4 Million Net Income Increased 179% to $14.2 Million Adjusted EBITDA Margin of 30% Raised Full-Year Revenue Guidance to $344 to $346 Million and Adjusted EBITDA Margin Guidance to 28% Conference Call Today at 8:30am Eastern Time
BURLINGTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its third quarter 2026 financial results on Thursday, November 5, 2026. Vericel's management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights.
Vericel Corporation (VCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Vericel's MACI already has an established commercial base, which I think gives them an easier path for future growth. MACI's arthroscopic delivery could also help it expand among surgeons. That's why VCEL's Burlington added capacity is timely if demand indeed increases. I also like that VCEL's recently gained BARDA contract helps with its Burn Care business. VCEL also has a potential UK launch and an ankle indication in the works.
BURLINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15th, 2026.
Vericel NASDAQ: VCEL reported record second-quarter revenue and raised its full-year outlook, citing continued growth in its MACI cartilage repair franchise and Burn Care business, along with improved profitability and cash generation.
Vericel Corporation (VCEL) Q2 2026 Earnings Call Transcript
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on VCEL and any ticker you trade — then tracks every position and per-strategy win rate.
